BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on the discovery, development, and commercialization of treatments for rare and serious diseases. The company's core business model centers on developing and commercializing oral small-molecule and protein therapeutics. BioCryst's primary revenue driver is ORLADEYO (berotralstat), a first-in-class oral, once-daily plasma kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients. The company also markets RAPIVAB (peramivir injection), an intravenous neuraminidase inhibitor for acute uncomplicated influenza. Geographically, BioCryst operates globally, with a strong commercial presence in the United States and Japan, though it recently announced the sale of its European operations to Neopharmed Gentili. In 2026, BioCryst strategically pivoted its research and development approach, winding down its internal discovery programs and closing its Discovery Center of Excellence in Birmingham, Alabama, to focus exclusively on acquiring and licensing external innovation. This includes the integration of navenibart, a long-acting injectable for HAE acquired through Astria Therapeutics, which complements its existing HAE franchise. The company faces competition in the rare disease and HAE markets but maintains a strong competitive position through its differentiated oral and injectable prophylactic offerings.
